

TAVR Procedural Optimization for Asian Patients with Small Valve Size

11TH AP VALVES & STRUCTURAL HEART 2022

12/08/2022 1000 TO 1010

Simon Lam MBBS(HK) FRCP (Glas) FHKCP FHKAM FACC FESC

Consultant & Honorary Clinical Associate Professor
School of Clinical Medicine, Department of Medicine,
Queen Mary Hospital, Hong Kong





TAVI in SAA - Definition of SAA

Definition of Small Aortic Annulus (SAA)

- ▶ Many cutoffs
- ▶ Some use cutoff based on THV used

Based on minimum size of BE-THV, Area < 330mm²

3D Area-derived Diameter (mm)	18.0	18.2	18.5	18.6	18.9	19.0	19.2	19.6	19.9	20.0	20.2	20.5	20.7	21.0	21.1	21.4	21.7	22.0	22.3	22.6	22.8	23.0	23.1	23.4
3D Annular Area (mm ²)	254	260	270	273	280	283	290	300	310	314	320	330	338	345	350	360	370	380	390	400	410	415	420	430
% Annular Area Over (+) or Under (-) Nominal by 3D CT	20 mm	29.1	26.2	21.5	20.1	17.1	15.9	13.1	9.3	5.8	4.5	2.5	-0.6	-3.0	-4.9	-6.3	-8.9							
	23 mm									29.3	26.9	23.0	20.1	17.7	16.0	12.8	9.7	6.8	4.1	1.5	-1.0	-2.2	-3.3	-5.6
	26 mm																			29.8	26.6	25.1	23.6	20.7
	29 mm																							

Puri R, Byrne J, Muller R, et al. Transcatheter Aortic Valve Implantation in patients with small aortic annuli using a 20mm balloon-expandable valve. Heart 2017; 103: 148-153

Okuyama K, Izumo M, Ochiai T, et al. New-generation Transcatheter Aortic Valves in patients with small aortic annuli. Cir J 2020; 84: 2015-2022

▶ Cutoff Area < 314mm²


3D Area-derived Diameter (mm)	18.0	18.2	18.5	18.6	18.9	19.0	19.2	19.6	19.9	20.0	20.2	20.5	20.7	21.0	21.1	21.4	21.7	22.0	22.3	22.6	22.8	23.0	23.1	23.4	
3D Annular Area (mm ²)	254	260	270	273	280	283	290	300	310	314	320	330	338	345	350	360	370	380	390	400	410	415	420	430	
% Annular Area Over (+) or Under (-) Nominal by 3D CT	20 mm	29.1	26.2	21.5	20.1	17.1	15.9	13.1	9.3	5.8	1.5	2.5	-0.6	-3.0	-4.9	-6.3	-8.9								
	23 mm										29.3	26.9	23.0	20.1	17.7	16.0	12.8	9.7	6.8	4.1	1.5	-1.0	-2.2	-3.3	-5.6
	26 mm																				29.8	26.6	25.1	23.6	20.7
	29 mm																								

Meguro K, Kumamaru H, Kohsaka S, et al. Transcatheter Aortic Valve Replacement in patients with a small annulus- from the Japanese Nationwide Registry (J-TVT). Circ J 2021; 85: 9670976

< 314mm² =
"extremely small"

Yashima F, Yamamoto M, Tanaka M, et al. Transcatheter aortic valve implantation in patients with an extremely small native aortic annulus: The OCEAN-TAVI Registry. Int J Cardiol. 2017 Aug 1;240:126-131

▶ Mean Diameter <=23mm (small annulus), <= 21 mm (extremely small annulus)

		
Size	23 mm	26 mm
Annulus Diameter (A)	17*/18-20 mm	20-23 mm
Annulus Perimeter†	53.4*/56.5-62.8 mm	62.8-72.3 mm
Sinus of Valsalva Diameter (Mean) (B)	≥25 mm	≥27 mm
Sinus of Valsalva Height (Mean) (C)	≥15 mm	≥15 mm

*Measurement for TAV-in-SAV only. | †Annulus Perimeter = Annulus Diameter x π
NOTE: Evolut PRO valve size selection is identical to Evolut™ B valve size selection criteria

Meguro K, Kumamaru H, Kohsaka S, et al. Transcatheter Aortic Valve Replacement in patients with a small annulus- from the Japanese Nationwide Registry (J-TVT). Circ J 2021; 85: 9670976

Abdelghani M, Mankerious N, Allali A, et al. Bioprosthetic valve performance after transcatheter aortic valve replacement with self-expanding versus balloon-expandable valves in large versus small aortic valve annuli – Insights from the CHOICE-Extend Registry. J Am Coll Cardiol Intv 2018; 11:2507-18

SAA in Asian Population


- ▶ Asian populations - significantly smaller AA diameter than European
 - ▶ $20.4 \pm 1.46\text{mm}$ vs $22.0 \pm 1.84\text{mm}$, $P < 0.01$

Watanabe Y, Hayashida K, Takayama M, Mitsudo K, et al. First direct comparison of clinical outcomes between European and Asian cohorts in transcatheter aortic valve implantation: the Massy study group vs. the PREVAIL JAPAN trial. J Cardiol. 2015 Feb;65(2):112-6. doi: 10.1016/j.jjcc.2014.05.001

BSA – Asian (1.4m^2) vs European ($1.72 \pm 0.18\text{m}^2$)



TAVI in SAA -
Verifying “Truly” Small Annuli





BAV 16mm 4cm X 20mm Balloon

1

F/82 DM IHD Severe AS

Area: 40% 245.9mm²
CT 20.6 mm X 14.5 mm
TEE 17mm





TAVI in SAA - Clinical Challenges of SAA

Problems associated with SAA

- ▶ Has been associated with poor outcomes after surgical AVR
 - ▶ Mortality
 - ▶ Ischaemic CV events and stroke
- ▶ Increased risk of Prosthesis-patient mismatch (PPM)
 - ▶ Increased risk of perioperative and overall mortality
 - ▶ Suboptimal valve haemodynamics
 - ▶ Less LV mass regression after AVR

Surgical Ways to tackle

Root enlargement

Stented prosthesis with supra-annular implantation

Stentless bioprosthesis

Sutureless valves



Transcatheter Aortic Valve Replacement in Patients With a Small Annulus

— From the Japanese Nationwide Registry (J-TVT) —

Kentaro Meguro, MD, PhD; Hiraku Kumamaru, PhD; Shun Kohsaka, MD, PhD;
 Takuya Hashimoto, MD, PhD; Ryota Kakizaki, MD, PhD; Tadashi Kitamura, MD, PhD;
 Hideyuki Shimizu, MD, PhD; Junya Ako, MD, PhD

Table 2. Clinical and Echocardiographic Outcomes Within 30 Days



	Small annulus (n=647)	Normal-sized annulus (n=5,223)	P value
Clinical outcomes			
30-day mortality	9 (1.4)	35 (0.7)	0.05
New pacemaker implantation	42 (6.5)	287 (5.5)	0.30
Stroke	14 (2.2)	75 (1.4)	0.15
Echocardiographic outcomes			
Effective orifice area (cm ²)	1.5 (1.2–1.8)	1.7 (1.4–2.0)	<0.001
Indexed effective orifice area (cm ² /m ²)	1.10 (0.92–1.35)	1.16 (0.96–1.39)	<0.001
Mean pressure gradient (mmHg)	10.0 (6.9–14.2)	8.5 (6.0–11.5)	<0.001
Paravalvular leakage ≥moderate	112 (17.3)	1,272 (24.4)	<0.001
Prosthesis-patient mismatch			
Severe	17 (2.6)	107 (2.0)	0.002
Moderate	101 (15.6)	580 (11.1)	
Insignificant	529 (81.8)	4,536 (86.8)	

Data are presented as n (%) and continuous variables are presented as medians (interquartile range).

Table 5. Clinical and Echocardiographic Outcomes Within 30 Days in Patients With SAPIEN3 20mm and Evolut R 23mm

	SAPIEN 3 20mm (n=90)	Evolut R 23mm (n=103)	P value
Clinical outcomes			
30-day mortality	0 (0.0)	0 (0.0)	1.00
New pacemaker implantation	4 (4.4)	10 (9.7)	0.16
Stroke	1 (1.1)	2 (1.9)	1.00
Echocardiographic outcomes			
Effective orifice area (cm ²)	1.2 (1.0–1.4)	1.4 (1.1–1.5)	0.002
Indexed effective orifice area (cm ² /m ²)	0.94 (0.78–1.06)	1.07 (0.84–1.24)	0.001
Mean pressure gradient (mmHg)	14.0 (10.0–18.5)	11.0 (7.0–14.0)	<0.001
Paravalvular leakage ≥moderate	13 (14.4)	17 (16.5)	0.69
Prosthesis-patient mismatch			
Severe	7 (7.8)	3 (2.9)	0.21
Moderate	24 (26.7)	23 (22.3)	
Insignificant	59 (65.6)	77 (74.8)	

Data are presented as n (%) and continuous variables are presented as medians (interquartile range).



Transcatheter aortic valve replacement with Evolut R versus Sapien 3 in Japanese patients with a small aortic annulus: The OCEAN-TAVI registry

OCEAN-TAVI Investigators

Small Annulus with 3rd generation devices – Evolut R sees to be superior to Sapien 3
Haemodynamic performance, up to 1 year after TAVR

All-cause mortality – no differences





TABLE 5 Postprocedural echocardiographic data at discharge and at 1 year after TAVR in the matched cohort

	Discharge				One year			
	Overall (N = 138)	Evolut R (N = 69)	Sapien 3 (N = 69)	p-Value	Overall (N = 97)	Evolut R (N = 47)	Sapien 3 (N = 50)	p-Value
Indexed EOA, cm ² /m ²	1.12 (0.95–1.35)	1.20 (1.01–1.46)	1.08 (0.90–1.28)	.01	1.04 (0.87–1.26)	1.21 (0.92–1.35)	0.96 (0.83–1.12)	<.001
Moderate PPM (iEOA ≤0.85), n (%)	17 (12.9)	5 (7.7)	12 (17.9)	.08	21 (21.6)	7 (14.9)	14 (28.0)	.12
Severe PPM (iEOA ≤0.65), n (%)	3 (2.3)	1 (1.5)	2 (3.0)	1.00	2 (2.1)	0 (0.0)	2 (4.0)	.50
Mean PG, mmHg	11.0 (8.0–13.8)	9.0 (6.0–12.0)	12.0 (10.0–14.8)	<.001	10.0 (8.0–14.8)	9.0 (6.0–11.9)	12.0 (9.9–16.3)	<.001
AR				.05				.24
None, n (%)	25 (18.5)	15 (22.4)	10 (14.7)		20 (20.6)	11 (23.4)	9 (18.0)	
Trivial, n (%)	52 (38.5)	19 (28.4)	33 (48.5)		38 (39.2)	16 (34.0)	22 (44.0)	
Mild, n (%)	58 (43.0)	33 (49.3)	25 (36.8)		36 (37.1)	17 (36.2)	19 (38.0)	
≥Moderate, n (%)	0 (0.0)	0 (0.0)	0 (0.0)		3 (3.1)	3 (6.4)	0 (0.0)	

Note: Values are medians (25th–75th percentiles) or n (%).

Abbreviations: AR, aortic regurgitation; EOA, effective orifice area; PG, pressure gradient; PPM, prosthesis-patient mismatch.

TABLE 6 Postprocedural echocardiographic data at discharge and at 1 year after TAVR in the extreme small annulus cohort

	Discharge				One year			
	Overall (N = 205)	Evolut R (N = 45)	Sapien 3 (N = 160)	p-Value	Overall (N = 145)	Evolut R (N = 29)	Sapien 3 (N = 116)	p-Value
Indexed EOA, cm ² /m ²	1.07 (0.90–1.27)	1.17 (0.99–1.46)	1.04 (0.88–1.18)	.002	1.00 (0.86–1.19)	1.20 (1.01–1.37)	0.97 (0.82–1.14)	<.001
Moderate PPM (iEOA ≤0.85), n (%)	34 (17.0)	4 (9.1)	30 (19.2)	.11	35 (24.1)	2 (6.9)	33 (28.4)	.015
Severe PPM (iEOA ≤0.65), n (%)	4 (2.0)	1 (2.3)	3 (1.9)	1.00	5 (3.4)	0 (0.0)	5 (4.3)	.26
Mean PG, mmHg	12.5 (9.0–16.3)	9.0 (6.0–11.0)	13.6 (10.0–16.9)	<0.001	13.1 (10.0–17.8)	8.0 (5.0–11.2)	15.0 (11.3–18.0)	<.001
AR				<0.001				.31
None, n (%)	46 (22.5)	8 (17.8)	38 (23.9)		51 (35.2)	7 (24.1)	44 (37.9)	
Trivial, n (%)	93 (45.6)	13 (28.9)	80 (50.3)		42 (29.0)	9 (31.0)	33 (28.4)	
Mild, n (%)	61 (29.9)	20 (44.4)	41 (25.8)		38 (26.2)	11 (37.9)	27 (23.3)	
≥Moderate, n (%)	4 (2.0)	4 (8.9)	0 (0.0)		8 (5.5)	2 (6.9)	6 (5.2)	

Note: Values are medians (25th–75th percentiles) or n (%).

Abbreviations: AR, aortic regurgitation; EOA, effective orifice area; PG, pressure gradient; PPM, prosthesis-patient mismatch.



TAVI in SAA -

Other concerns of TAVI in SAA

Additional Technical Concerns – TAVI in SAA

- ▶ Risk of Annulus Rupture
 - ▶ Relative valve oversizing
 - ▶ In particular dense calcifications
 - ▶ Low BSA
- ▶ Acute Coronary Obstruction
- ▶ Vascular Complications – Small femoral arteries
- ▶ Coronary reassess
- ▶ Future management of TAV bioprosthesis failure


Techniques to optimize TAVI in SAA

- ▶ Verify with multiple methods to ascertain small annulus size in the first place
- ▶ Enhancement in haemodynamic performance
 - ▶ Relatively higher implants for S3/Intra-annular valve platform
 - ▶ Use of supra-annular TAV
 - ▶ Optimization of TAV frame expansion (balloon pre dil/post dil, volume adj)
- ▶ Selection of BEV/SEV – take the whole aortic valve/annulus complex anatomy into considerations
 - ▶ STJ/Sinus/LVOT
- ▶ Device Size selection in borderline cases
- ▶ Coronary protection



TAVI in SAA - SAPIEN 3

Im: 1/79
Se: 25



Queen Mary Hospital
1
Coro 3040 Log

WL: 119 WW: 118 [D]
LAO: 13 CRA: 9

5/11/2018 3:03:46 PM

Im: 1/75
Se: 27



Queen Mary Hospital
1
Coro 3040 Log

WL: 119 WW: 118 [D]
RAO: 3 CRA: 6

5/11/2018 3:14:57 PM

Area 311.1mm²
Perimeter 64.1mm

Average 20.3mm

2

SAPIEN 3 THV Sizing: Confirm Size

Chung Tuk Sim

Edwards SAPIEN 3 #20mm
N(+vol) / 23(-vol)

NOTE: Systolic measurements are recommended
Need some more over size

3D Area Sealing Zones

Mid left G + thickening mainly

(40%)
Circumferential
Min 16.1mm
Max 22.9mm
Average 19.5mm
Circumferential 19.2mm
Perimeter 19.8mm
Area = 285.1mm²

3D Area - derived Diameter (mm)	20.0	20.2	20.5	20.7	21.0	21.1	21.4	21.7	22.0	22.3	22.6	22.8	23.0	23.1	23.4	23.7	23.9	24.0	24.2	24.7	
3D Annular Area (mm ²)	314	320	330	338	346	350	360	370	380	390	400	410	415	420	430	440	450	452	460	480	
23mm	29.3	26.9	23.0	20.1	17.3	16.0	12.8	9.7	6.8	4.0	1.5	-1.0	-2.2	-3.3	-5.6	-7.7	-9.8				
26mm												29.8	26.6	25.1	23.6	20.7	18.0	15.3	14.8	12.8	8.1
29mm																					

(50%)
Circumferential
Min 15.6mm
Max 22.3mm
Average 19.6mm
Circumferential 19.1mm
Perimeter 19.7mm
Area = 288.7mm²
Perimeter 62.2mm

3D Area - derived Diameter (mm)	25.0	25.2	25.5	25.7	26.0	26.2	26.4	26.5	26.7	26.9	27.2	27.4	27.6	27.9	28.0	28.1	28.3	28.5	28.8	29.0	29.2	29.4	29.5	29.6	29.9	30.1	30.3	
3D Annular Area (mm ²)	490	500	510	520	530	540	546	550	560	570	580	590	600	610	615	620	630	640	650	660	670	680	683	690	700	710	720	
23mm																												
26mm																												
29mm																												

NOTE: Bold = recommended Sealing Zones relate only to valves that are deployed with nominal volumes

NOTE: All values presented are based on nominal/recommended inflation volumes

Circumferential
R 15.9mm
L 17.7mm

size 17
Duro - RAO & CRAN
diameter 17mm
3 main

Size 25 x 27 x 27

Complex but too small
Circumferential small

R Mantle ok ✓







L size high but ok.

Best alignment angle
LAO 23°
CAU 3°




3

Area 288.7mm²
Perimeter 62.2mm
Average 19.5mm



Im: 1/51
Se: 13



Queen Mary Hospital
1
Coro 3040 Log

WL: 119 WW: 118 [D]
RAO: 25

2/3/2020 3:01:14 pm

Im: 1/200
Se: 26





Queen Mary Hospital
1
Coro 3040 Log

WL: 119 WW: 122 [D]
RAO: 10 CAU: 14


2/3/2020 3:20:24 pm

Delivery Nominal +1 ml



Post dilatation Delivery System Balloon additional +1 ml (Nominal + 2)

SAPIEN 3 Valve Sizing: Confirm THV Size

SFS 5/5/2017 SAPIEN 3 # MAC or Fluo. 
 Low L ostium - RAV (trans spig/ostia) 22mm/23mm

NOTE:
Systolic measurements are recommended

[30% phase]
 MM 17.2mm
 Max 22.8mm
 (average 20.0mm)
 Area 311.6mm²

3D Area - derived Diameter (mm)	20.0	20.2	20.5	20.7	21.0	21.1	21.4	21.7	22.0	22.3	22.6	22.8	23.0	23.1	23.4	23.7	23.9	24.0	24.2	24.7	
3D Annular Area (mm ²)	314	320	330	338	346	350	360	370	380	390	400	410	415	420	430	440	450	452	460	480	
23mm	29.3	26.9	23.0	20.1	17.3	16.0	12.8	9.7	6.8	4.0	1.5	-1.0	-2.2	-3.3	-5.6	-7.7	-9.8				
26mm											29.8	26.6	25.1	23.6	20.7	18.0	15.3	14.8	12.8	8.1	
29mm																					

Coro ostium
 R. 14.8mm
 L. 8.1mm
 (+ Anterior)

3D Area - derived Diameter (mm)	25.0	25.2	25.5	25.7	26.0	26.2	26.4	26.5	26.7	26.9	27.2	27.4	27.6	27.9	28.0	28.1	28.3	28.5	28.8	29.0	29.2	29.4	29.5	29.6	29.9	30.1	30.3	
3D Annular Area (mm ²)	490	500	510	520	530	540	546	550	560	570	580	590	600	610	615	620	630	640	650	660	670	680	683	690	700	710	720	
23mm																												
26mm																												
29mm																												

NOTE:
 Bold = recommended Sealing Zones relate only to valves that are deployed with nominal volumes

NOTE:
 All values presented are based on nominal/recommended inflation volumes

4





Area 311.6mm²
 Average 20.0mm




Bilateral fem ✓
 OK (R)

3 months (LAO 9° CAU 19°)

Beta-Digant angle (angle) → LAO 7° CAU 17°



Im: 1/266
Se: 26




Queen Mary Hospital
0627-2017
XA
Left Coronary 15 fps

[WL: 129 WW: 190 [D]
LAO: 12 CAU: 27

5/5/2017 11:14:26 AM

Im: 1/57
Se: 29



Queen Mary Hospital
0627-2017
XA
Left Coronary 15 fps

[WL: 129 WW: 190 [D]
LAO: 12 CAU: 36

5/5/2017 11:20:40 AM




TAVI in SAA - EVOLUT PRO/+

Small annulus relatively

Evolut™ TAVR Evolut PRO 23mm




PATIENT EVALUATION CRITERIA



Aortic Annulus (35% Phase)







Min 16.4mm
Max 21.3mm
Average 18.9mm

Area = 280.6mm²
Perimeter = 60.6mm
Perimeter derived = 19.3mm

Valve Size Selection	Evolut™ PRO Bioprosthesis	Evolut™ R Bioprosthesis		
				
Size	23 mm	26 mm	29 mm	34 mm
Annulus Diameter (A)	17*/18-20 mm	20-23 mm	23-26 mm	26-30 mm
Annulus Perimeter*	53.4*/56.5-62.8 mm	62.8-72.3 mm	72.3-81.7 mm	81.7-94.2 mm
Sinus of Valsalva Diameter (Mean) (B)	≥25 mm	≥27 mm	≥29 mm	≥31 mm
Sinus of Valsalva Height (Mean) (C)	≥15 mm	≥15 mm	≥15 mm	≥16 mm

Selection Criteria


Access Consideration by MSCT	IFU Guidance by MSCT
Minimum Transarterial Access Vessel Diameter	Evolut PRO 23/26/29 TAVs and Evolut R 34 TAV ≥ 5.0 mm Evolut R 23/26/29 TAVs ≥ 5.0 mm
Aortic Root Angulation, Femoral Access	Not recommended if >70 degrees.
Aortic Root Angulation, Left Subclavian	Not recommended if >70 degrees.*
Aortic Root Angulation, Right Subclavian	Not recommended if >30 degrees.*
Vascular Access Location, Direct Aortic Access	Ascending aorta access site ≥60 mm from basal plane.**



Area 280.6mm²
Perimeter 60.6mm
Average 18.9mm

6

Im: 1/74
Se: 9




Queen Mary Hospital
1384-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
CAU: 10

18/9/2019 3:23:09 pm

Im: 1/136
Se: 16




Queen Mary Hospital
1384-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
CAU: 10

18/9/2019 3:38:38 pm



Im: 1/62
Se: 19




Queen Mary Hospital
1384-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
LAO: 30 CAU: 20

18/9/2019 3:44:19 pm

Im: 1/63
Se: 28



Queen Mary Hospital
1384-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
LAO: 10 CAU: 11

18/9/2019 4:00:36 pm



TAVI in SAA - ACURATE NEO

Wong KK / *ACURATE neo S=23mm*

Boston Scientific

Aortic annulus (30% phase)

min 18.7mm

max 22.7mm

average 20.7mm

area derived 20.4mm

perimeter derived 20.7mm


ACURATE neo™

Aortic Valve

perimeter
65.0mm

*Relatively smaller than FM annulus size
Not too much calcium*

(Stilus big - ✓)



Valve Size	S - 23 mm	M - 25 mm	L - 27 mm
Order Number	SYM-SV23-002	SYM-SV25-002	SYM-SV27-002
Aortic annulus diameter* (mm)	21mm ≤ annulus Ø ≤ 23 mm	23mm < annulus Ø ≤ 25 mm	25mm < annulus Ø ≤ 27 mm
Aortic annulus perimeter (mm)	66 mm ≤ annulus C ≤ 72 mm	72 mm < annulus C ≤ 79 mm	79 mm < annulus C ≤ 85 mm


right cor
- 16.0mm

Left cor
- 14.2mm ✓

Femoral -

* CT based measurement: Perimeter derived annulus.

9 SH-531901-AA FEB2018 © 2018 Boston Scientific Corporation or its affiliates. All rights reserved.



*Best alignment angle =
(3-40mm)*







EDUCARE

LAo 17°
CAU 4°


7

Perimeter 65.0mm

Average 20.7mm



Im: 1/4
Se: 30




Queen Mary Hospital
0104-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
LAO: 15 CAU: 8

18/1/2019 1:15:53 PM

Im: 153/212
Se: 35




Queen Mary Hospital
0104-2019
XA
Fluoroscopy

WL: 115 WW: 213 [D]
LAO: 15 CAU: 8

18/1/2019 1:16:56 PM

Im: 1/92
Se: 48




Queen Mary Hospital
0104-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
LAO: 13 CAU: 8

18/1/2019 1:36:27 PM


Im: 1/89
Se: 54



Queen Mary Hospital
0104-2019
XA
Left Coronary 15 fps

WL: 129 WW: 190 [D]
LAO: 13 CAU: 8

18/1/2019 1:47:11 PM

- 
- ▶ Gradient remained PG/MG 11/6mmHg at 3 years
 - ▶ CT coro – progression of underlying IHD plan coro+/-PCI

Im: 1/40
Se: 3



Queen Mary Hospital
0833-2022
Cardiac Cath
Exposure 7.5 fps

Im: 1/35
Se: 8



Queen Mary Hospital
0833-2022
Cardiac Cath
Exposure 7.5 fps

Im: 1/32
Se: 57



Queen Mary Hospital
0833-2022
Cardiac Cath
StantBoost LCA 30 fps

Im: 1/145
Se: 69



Queen Mary Hospital
0833-2022
Cardiac Cath
Left Coronary 30 fps



TAVI in SAA - Conclusion

Conclusion

- ▶ Small/(extremely small) Aortic Annulus commonly seen in Asian Population
- ▶ Verify the measurements
- ▶ Taking whole AV Complex into considerations
- ▶ Procedural Optimization
 - ▶ Techniques
 - ▶ Avoid complications
 - ▶ Device selection
- ▶ Heart Team Evaluation
- ▶ Patient Factors and Expectations
- ▶ Systematic and careful long term FU



Supporting Organizations:



HONG KONG VALVES 2022

15-16th October 2022 (Sat & Sun)

Board Room, Faculty Administration Wing,
Faculty of Medicine Building, 21 Sassoon Road, Hong Kong

Case demonstrations from local and overseas centers

Plenary lectures by overseas & local experts

- Life-time management of patients with valvular heart disease
- Innovative mitral and tricuspid transcatheter valve therapies
- Structural heart and coronary interventions crossover - CHIP & hemodynamics support ^{NEW}
- Electrophysiology and device therapies for structural heart disease ^{NEW}

Hands-on workshops

- Cardiac anatomical surgical basics with Hands-on Web-lab
- Point-of-care echocardiography with live demo: from A to Z
- Cardiac catheterization skills for surgeons and interventionalists

SECOND ANNOUNCEMENT



Conference Secretariat
hkvalve@hku.hk
http://hongkongvalves.com



<https://onemediachannel.com/event/register/HKValve2022>

Thank you!

HKU
Med